Main Menu

NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

GeNeuro SA (PA: GNRO)

 
GNRO Technical Analysis
1
As on 2nd Mar 2026 GNRO STOCK Price closed @ 0.03 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

GNROSTOCK Price

Open 0.03 Change Price %
High 0.03 1 Day N/A N/A
Low 0.03 1 Week 0.00 0.00
Close 0.03 1 Month 0.00 0.00
Volume N/A 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
PA France Most Active Stocks
FTI 5.91 -1.66%
VIEDS 0.72 4.35%
ALNEV 0.00 %
TTE 69.36 %
ENGI 28.60 %
ALEUP 0.03 %
DSY 18.47 %
CGG 0.69 -2.82%
CS 40.53 %
ACA 18.39 %
 
PA France Top Gainers Stocks
2MX 7.46 8.43%
ATA 0.13 8.33%
ATA 0.13 8.33%
ATA 0.13 8.33%
ATA 0.13 8.33%
ATA 0.13 8.33%
ALTBG 2.88 8.27%
ALP 21.50 6.44%
ALP 21.50 6.44%
ALANT 4.68 6.36%
 
PA France Top Losers Stocks
AKOM 4.06 -37.05%
AKOM 4.06 -37.05%
FPN 0.02 -33.33%
ORP 7.90 -12.03%
MLMON 0.88 -12.00%
FALG 0.56 -8.20%
PROL 0.24 -7.69%
LFDE 44.20 -7.14%
ALD 6.87 -5.89%
ALD 6.87 -5.89%
 
 
GNRO
Daily Charts		 GNRO
Intraday Charts		 Whats New @
Bazaartrend		 GNRO
Free Analysis
 
GNRO Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
GNRO Forecast March 2026
Share
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
GNRO Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
GNRO Forecast2026
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
GNRO Other Details
Segment EQ
Market Capital 84817368.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
GNRO Address
GNRO
 
GNRO Latest News
 
Your Comments and Response on GeNeuro SA
 
GNRO Business Profile
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland. Address: 3 chemin du PrE-Fleuri, Plan-les-Ouates, Switzerland, 1228
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service